Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation

• Main Authors: Dongdong Li, Meng Zhang, Fan Xu, Yingzhi Chen, Binfan Chen, Ya Chang, Huihai Zhong, Hongyue Jin, Yongzhuo Huang
• Format: Article
• Language: English
• Published: Elsevier 2018-01-01
• Series: Acta Pharmaceutica Sinica B
• Subjects: Photothermal therapy; Paclitaxel; Combination therapy; Gold nanorods; Albumin; Tumor-associated macrophage
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211383517302551
• ISSN: 2211-3835; 2211-3843

Nanotechnology-based photothermal therapy has attracted great attention in the past decade. Nevertheless, photothermal therapy has some inherent drawbacks, such as the uneven heat production and limited laser penetration, often leading to insufficient treatment outcomes. Here, we developed a combination strategy to improve cancer therapy. The biomimetic albumin-modified gold nanorods (AuNRs) were prepared with incorporation of paclitaxel (PTX). This therapeutic system was characterized by several features. First, the albumin modification enhanced the biocompatibility and colloidal stability. Second, the surface-coated albumin promoted cellular uptake via the albumin-binding protein pathway. Third, PTX was incorporated via hydrophobic interaction between PTX and the albumin lipophilic domain. Fourth, the system can be used for combined photothermo-chemotherapy for yielding synergistic effects. The antitumor activity of the system was evaluated both in vitro and in vivo using the HCT116 colon cancer cell and tumor model. The combination therapy was found with an enhanced treatment efficiency and no obvious side effect. Most importantly, the thermal effect was also discovered with the ability to modulate the tumor microenvironments and suppress the macrophages polarization towards the M2 pro-tumor phenotype. It could be a mechanism for photothermal immunotherapy. The combination strategy and the system provide a potential method for cancer therapy.